8-K current report · filed Aug 5, 2026

Revolution Medicines Inc (RVMD) 8-K Current Report: August 5, 2026

Item 2.02Item EX-99.1RVMD overview

Short answer

Revolution Medicines Inc (RVMD) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results announced for quarter ended June 30, 2026.

Revolution Medicines Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q2 2026 financial results announced for quarter ended June 30, 2026
  • Full earnings release furnished as Exhibit 99.1, containing detailed operating and financial results
  • Results announcement provides investors the company’s latest quarterly performance update

Item EX-99.1 · Exhibit EX-99.1

  • FDA accepted daraxonrasib’s NDA for previously treated metastatic pancreatic cancer, advancing the lead program toward potential commercialization
  • Expanded Access Program reached more than 2,000 patients across nearly 50 U.S. states and Puerto Rico, signaling substantial physician and patient demand
  • Cash, equivalents and marketable securities totaled $3.9 billion, supported by $2,225.0 million of April financing and a $250.0 million Royalty Pharma payment
  • Second-quarter R&D expenses rose to $394.9 million and G&A to $110.2 million, reflecting late-stage trials and commercial launch preparation
  • Net loss widened to $644.4 million, including a $151.0 million non-cash warrant fair-value charge; 2026 GAAP operating expense guidance increased to $2.1-$2.2 billion

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Revolution Medicines Inc 8-K filings

Get the next RVMD 8-K as it lands

Follow RVMD for push alerts, or ask the research agent what this filing means.